A086900 Stock Overview
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea.
Medy-Tox Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩131,000.00|
|52 Week High||₩150,400.00|
|52 Week Low||₩99,700.00|
|1 Month Change||18.98%|
|3 Month Change||5.99%|
|1 Year Change||-8.91%|
|3 Year Change||-50.25%|
|5 Year Change||-65.94%|
|Change since IPO||918.19%|
Recent News & Updates
|A086900||KR Biotechs||KR Market|
Return vs Industry: A086900 exceeded the KR Biotechs industry which returned -41% over the past year.
Return vs Market: A086900 exceeded the KR Market which returned -24.1% over the past year.
|A086900 Average Weekly Movement||5.7%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||6.5%|
|10% most volatile stocks in KR Market||11.6%|
|10% least volatile stocks in KR Market||3.8%|
Stable Share Price: A086900 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A086900's weekly volatility (6%) has been stable over the past year.
About the Company
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials.
Medy-Tox Inc. Fundamentals Summary
|A086900 fundamental statistics|
Is A086900 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A086900 income statement (TTM)|
|Cost of Revenue||₩72.86b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||3.90k|
|Net Profit Margin||12.75%|
How did A086900 perform over the long term?See historical performance and comparison